AssetMark Inc’s VanEck Biotech ETF BBH Stock Holding History

AssetMark Inc’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-140	Closed	-$22K	–	3014
2025 Q1	$22K	Sell	140 -244	-64%	-$39.6K	﹤0.01%	1685
2024 Q4	$60.3K	Sell	384 -3,081	-89%	-$518K	﹤0.01%	1380
2024 Q3	$615K	Sell	3,465 -32	-0.9%	-$5.68K	﹤0.01%	865
2024 Q2	$589K	Sell	3,497 -796	-19%	-$130K	﹤0.01%	848
2024 Q1	$714K	Buy	4,293 +2,514	+141%	+$416K	﹤0.01%	778
2023 Q4	$294K	Buy	1,779 +911	+105%	+$140K	﹤0.01%	858
2023 Q3	$135K	Buy	+868	New	+$139K	﹤0.01%	937

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AssetMark Inc's BBH Position: Q2 2025 in Review

AssetMark Inc sold out of VanEck Biotech ETF (BBH) in Q2 2025, closing a stake of 140 shares — an estimated $22K sold.

AssetMark Inc first reported a position in BBH in Q3 2023 and held it in 7 quarters. The position peaked at $714K in Q1 2024. 98 funds tracked by Wall St. Rank hold BBH as of Q2 2025.

AssetMark Inc reported no remaining VanEck Biotech ETF position as of Q2 2025 after selling out during the quarter.
AssetMark Inc sold 140 VanEck Biotech ETF shares in Q2 2025, an estimated $22K.
AssetMark Inc first reported a position in VanEck Biotech ETF in Q3 2023 and held it in 7 quarters.
AssetMark Inc's VanEck Biotech ETF position peaked at $714K in Q1 2024.
98 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2025.

Based on AssetMark Inc's 13F filing for Q2 2025, filed 4 Aug 2025.